Role of antibody-based therapy in indolent non-Hodgkin's lymphoma

Leuk Res Rep. 2021 Oct 24;16:100275. doi: 10.1016/j.lrr.2021.100275. eCollection 2021.ABSTRACTMonoclonal antibodies (mAb) for indolent non-Hodgkin's lymphoma (iNHL) including follicular and marginal zone lymphomas was a key therapeutic development that changed the natural history of these diseases. Rituximab, a chimeric anti-CD20 mAb, was the first immunotherapy ever used in cancer, and a current cornerstone of lymphoma therapies. Since, we saw development of humanized antibodies, next generations anti-CD20, mAbs targeting other markers on tumor cells (CD19 and CD22), its microenvironment (PD-1, CD47), antibody drug conjugates and bispecific T cell engagers. Given their activity, safety and specificity, mAbs are well poised to remain an essential therapeutic tool for iNHL and other malignancies.PMID:34765437 | PMC:PMC8569585 | DOI:10.1016/j.lrr.2021.100275
Source: Cell Research - Category: Cytology Authors: Source Type: research

Related Links:

ConclusionNHL-associated PNS are rare and bear unfavorable prognosis. The diagnosis should not be overlooked even in seronegative patients.
Source: Neurological Sciences - Category: Neurology Source Type: research
AbstractThe PI3K δ-inhibitor Idelalisib is approved for the treatment of Non-Hodgkin lymphoma. However, its use has been decreased within the last years due to deleterious infections such as cytomegalovirus and pneumocystis jirovecii. Here, we have investigated the effect of Idelalisib on human monocyte-derived den dritic cells (DCs) as important players in the induction of immune responses. We found that Idelalisib-treated DCs displayed impaired T cell stimulatory function. PI3Kδ inhibition during differentiation resulted in decreased Interleukin-12, Interleukin-13 and TNFα production by DCs after lipopo...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
Br J Radiol. 2021 Aug 10:20210098. doi: 10.1259/bjr.20210098. Online ahead of print.ABSTRACTRadiation therapy has the potential to modulate the immune system in a variety of ways, and given the critical role of the immune system in cancer elimination, it is becoming increasingly important to understand how radiation can be strategically implemented in conjunction with approved immunotherapies to improve the cancer patient's chance of cure and/or quality of life. Current successful, approved cancer immunotherapies fall into two broad classes: antibodies and cellular therapies. Approved cellular therapies thus far consist of...
Source: The British Journal of Radiology - Category: Radiology Authors: Source Type: research
Non-Hodgkin’s lymphoma (NHL) is a cancer that starts in the lymphatic system. In NHL, the important part of the immune system, a type of white blood cells called lymphocytes become cancerous. NHL subtypes include marginal zone lymphoma, small lymphocytic lymphoma, follicular lymphoma (FL), and lymphoplasmacytic lymphoma. The disease can emerge in either aggressive or indolent form. 5-year survival duration after diagnosis is poor among patients with aggressive/relapsing form of NHL. Therefore, it is necessary to understand the molecular mechanisms of pathogenesis involved in NHL establishment and progression. In the ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Basel, 11 May 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 19 approved and investigational medicines across 20 cancer types will be presented at the 2021 ASCO Annual Meeting, which will be held 4-8 June, 2021. A total of 132 abstracts that include a Roche medicine will be presented at this year's meeting. These data advance oncology by showing the importance of making patient-centric treatment decisions and providing tailored medical care based on specific cancer types.“We will be presenting data from across our diverse oncology portfolio that has the potential to he...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Transl Oncol. 2021 Mar 28;14(6):101070. doi: 10.1016/j.tranon.2021.101070. Online ahead of print.ABSTRACTCell-based immunotherapies have been selected for the front-line cancer treatment approaches. Among them, CAR-T cells have shown extraordinary effects in hematologic diseases including chemotherapy-resistant acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma (NHL). In this approach, autologous T cells isolated from the patient's body genetically engineered to express a tumor specific synthetic receptor against a tumor antigen, then these cells expanded ex vivo and re-infusio...
Source: Translational Oncology - Category: Cancer & Oncology Authors: Source Type: research
agrave; Ribeiro Roué For years, immunotherapy has been considered a viable and attractive treatment option for patients with cancer. Among the immunotherapy arsenal, the targeting of intratumoral immune cells by immune-checkpoint inhibitory agents has recently revolutionised the treatment of several subtypes of tumours. These approaches, aimed at restoring an effective antitumour immunity, rapidly reached the market thanks to the simultaneous identification of inhibitory signals that dampen an effective antitumor response in a large variety of neoplastic cells and the clinical development of monoclonal ant...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Viruses, Vol. 12, Pages 852: Contribution of Human Retroviruses to Disease Development—A Focus on the HIV– and HERV–Cancer Relationships and Treatment Strategies Viruses doi: 10.3390/v12080852 Authors: Ching-Hsuan Liu Nicole Grandi Lalitha Palanivelu Enzo Tramontano Liang-Tzung Lin Animal retroviruses are known for their transforming potential, and this is also true for the ones hosted by humans, which have gathered expanding attention as one of the potent causative agents in various disease, including specific cancer types. For instance, Human T Lymphotropic virus (HTLV) is a well-studied...
Source: Viruses - Category: Virology Authors: Tags: Review Source Type: research
Basel, 14 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its investigational CD20xCD3 T-cell engaging bispecific mosunetuzumab has been granted Breakthrough Therapy Designation (BTD) by the US Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma who have received at least two prior systemic therapies.“We are pleased that the FDA has granted Breakthrough Therapy Designation to mosunetuzumab, recognising the promising early efficacy data for this molecule and the remaining unmet need in follicular lymphoma,” said Levi Gar...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
ConclusionAutologous anti-CD19, anti-CD22, and anti-CD20 CAR-T cell therapies targeting multiple tumor antigens could be an innovative and sound treatment for children with r/r BL, provided that they are closely monitored during treatment.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Cytology | Hodgkin's Disease | Immunotherapy | Lymphoma | Non-Hodgkin's Lymphoma | Rituxan